JPWO2020117987A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020117987A5 JPWO2020117987A5 JP2021532071A JP2021532071A JPWO2020117987A5 JP WO2020117987 A5 JPWO2020117987 A5 JP WO2020117987A5 JP 2021532071 A JP2021532071 A JP 2021532071A JP 2021532071 A JP2021532071 A JP 2021532071A JP WO2020117987 A5 JPWO2020117987 A5 JP WO2020117987A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- aryl
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted Chemical class 0.000 claims 99
- 239000003795 chemical substances by application Substances 0.000 claims 39
- 125000004429 atom Chemical group 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 229910052799 carbon Inorganic materials 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 15
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 15
- 125000004122 cyclic group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 102100038495 Bile acid receptor Human genes 0.000 claims 12
- 108070000005 Bile acid receptors Proteins 0.000 claims 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 12
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 12
- 229940125388 beta agonist Drugs 0.000 claims 12
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 230000002503 metabolic effect Effects 0.000 claims 12
- 229940075993 receptor modulator Drugs 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 230000003510 anti-fibrotic effect Effects 0.000 claims 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical group OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 6
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 claims 6
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims 6
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 claims 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 108010019598 Liraglutide Proteins 0.000 claims 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 6
- 102100040918 Pro-glucagon Human genes 0.000 claims 6
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- FEDXWGXJVSAPGM-UHFFFAOYSA-N ethyl henicosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC FEDXWGXJVSAPGM-UHFFFAOYSA-N 0.000 claims 6
- 229940125753 fibrate Drugs 0.000 claims 6
- 235000021323 fish oil Nutrition 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 229960002701 liraglutide Drugs 0.000 claims 6
- 229910052698 phosphorus Inorganic materials 0.000 claims 6
- 239000011574 phosphorus Substances 0.000 claims 6
- 229950011186 semaglutide Drugs 0.000 claims 6
- 108010060325 semaglutide Proteins 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 3
- 108010011459 Exenatide Proteins 0.000 claims 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 3
- 108010057186 Insulin Glargine Proteins 0.000 claims 3
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 3
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims 3
- 102000005766 Mitochondrial Membrane Transport Proteins Human genes 0.000 claims 3
- 108010045701 Mitochondrial Membrane Transport Proteins Proteins 0.000 claims 3
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 3
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 3
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 3
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 claims 3
- 229940121886 Thyroid hormone receptor agonist Drugs 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 229960004733 albiglutide Drugs 0.000 claims 3
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 3
- 229960001214 clofibrate Drugs 0.000 claims 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960005175 dulaglutide Drugs 0.000 claims 3
- 108010005794 dulaglutide Proteins 0.000 claims 3
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 3
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical group CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 3
- VCSQUSNNIFZJAP-AAQCHOMXSA-N ethyl (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CCOC(=O)CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC VCSQUSNNIFZJAP-AAQCHOMXSA-N 0.000 claims 3
- 125000004494 ethyl ester group Chemical group 0.000 claims 3
- VBOWIMINMHXKRB-UHFFFAOYSA-N ethyl hexadeca-2,4,6-trienoate Chemical compound CCCCCCCCCC=CC=CC=CC(=O)OCC VBOWIMINMHXKRB-UHFFFAOYSA-N 0.000 claims 3
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 claims 3
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 claims 3
- RIDOSNBWMUADGT-AFSLFLIVSA-N ethyl stearidonate Chemical compound CCOC(=O)CCCC\C=C/C\C=C/C\C=C/C\C=C/CC RIDOSNBWMUADGT-AFSLFLIVSA-N 0.000 claims 3
- CCOFRUKSYYGJRC-UHFFFAOYSA-N ethyl tetracosa-2,4,6,8,10-pentaenoate Chemical compound C(C=CC=CC=CC=CC=CCCCCCCCCCCCCC)(=O)OCC CCOFRUKSYYGJRC-UHFFFAOYSA-N 0.000 claims 3
- 229960001519 exenatide Drugs 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 229960002297 fenofibrate Drugs 0.000 claims 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 3
- 229960000701 fenofibric acid Drugs 0.000 claims 3
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 claims 3
- 229960003627 gemfibrozil Drugs 0.000 claims 3
- 229960002869 insulin glargine Drugs 0.000 claims 3
- 229960001093 lixisenatide Drugs 0.000 claims 3
- 108010004367 lixisenatide Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229940076155 protein modulator Drugs 0.000 claims 3
- 108700027806 rGLP-1 Proteins 0.000 claims 3
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000005587 carbonate group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000007863 steatosis Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000001187 Collagen Type III Human genes 0.000 claims 1
- 108010069502 Collagen Type III Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199809A JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775799P | 2018-12-05 | 2018-12-05 | |
| US62/775,799 | 2018-12-05 | ||
| US201962821303P | 2019-03-20 | 2019-03-20 | |
| US62/821,303 | 2019-03-20 | ||
| PCT/US2019/064548 WO2020117987A1 (en) | 2018-12-05 | 2019-12-04 | Compositions and methods for the treatment of liver disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Division JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510690A JP2022510690A (ja) | 2022-01-27 |
| JP2022510690A5 JP2022510690A5 (https=) | 2022-12-13 |
| JPWO2020117987A5 true JPWO2020117987A5 (https=) | 2022-12-13 |
Family
ID=70974003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532071A Pending JP2022510690A (ja) | 2018-12-05 | 2019-12-04 | 肝障害の処置のための組成物及び方法 |
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220016136A1 (https=) |
| EP (1) | EP3890748A4 (https=) |
| JP (2) | JP2022510690A (https=) |
| KR (1) | KR20210099612A (https=) |
| CN (1) | CN113365637A (https=) |
| AU (2) | AU2019394947B2 (https=) |
| BR (1) | BR112021010916A2 (https=) |
| CA (1) | CA3121620A1 (https=) |
| MX (5) | MX2021006575A (https=) |
| WO (1) | WO2020117987A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CN115093404B (zh) * | 2020-07-17 | 2024-06-21 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| WO2025193816A1 (en) * | 2024-03-14 | 2025-09-18 | Viking Therapeutics, Inc. | Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128058A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EA024697B1 (ru) * | 2009-04-27 | 2016-10-31 | Иммурон Лимитед | Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP3438087A1 (en) * | 2012-05-02 | 2019-02-06 | Boehringer Ingelheim International GmbH | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| CN110536682B (zh) * | 2017-04-18 | 2023-01-06 | 基恩菲特公司 | 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合 |
| US11707472B2 (en) * | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
-
2019
- 2019-12-04 EP EP19893549.6A patent/EP3890748A4/en active Pending
- 2019-12-04 BR BR112021010916-1A patent/BR112021010916A2/pt unknown
- 2019-12-04 CA CA3121620A patent/CA3121620A1/en active Pending
- 2019-12-04 CN CN201980091024.3A patent/CN113365637A/zh active Pending
- 2019-12-04 US US17/311,014 patent/US20220016136A1/en active Pending
- 2019-12-04 WO PCT/US2019/064548 patent/WO2020117987A1/en not_active Ceased
- 2019-12-04 MX MX2021006575A patent/MX2021006575A/es unknown
- 2019-12-04 KR KR1020217020331A patent/KR20210099612A/ko active Pending
- 2019-12-04 JP JP2021532071A patent/JP2022510690A/ja active Pending
- 2019-12-04 AU AU2019394947A patent/AU2019394947B2/en active Active
-
2021
- 2021-06-03 MX MX2024001203A patent/MX2024001203A/es unknown
- 2021-06-03 MX MX2024001205A patent/MX2024001205A/es unknown
- 2021-06-03 MX MX2024001201A patent/MX2024001201A/es unknown
- 2021-06-03 MX MX2024001204A patent/MX2024001204A/es unknown
-
2024
- 2024-11-15 JP JP2024199809A patent/JP2025028061A/ja active Pending
-
2025
- 2025-08-22 AU AU2025220854A patent/AU2025220854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020117987A5 (https=) | ||
| ES3031577T3 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2023002662A5 (https=) | ||
| TWI519312B (zh) | 脂肪酸菸鹼酸共軛物及其用途 | |
| EP0753301B1 (en) | Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic | |
| US20130190327A1 (en) | Bis-fatty acid conjugates and their uses | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP7368354B2 (ja) | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 | |
| JP2009530393A5 (https=) | ||
| EA021174B1 (ru) | Применение ингибиторов дипептидилпептидазы | |
| JP2015519322A5 (https=) | ||
| US20090074844A1 (en) | Trenadermal absorption preparation | |
| JP6959246B2 (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| KR20090123863A (ko) | 췌장 당뇨병 치료용 엑세나티드 및 달라르긴-기반 약학적 제제 | |
| JP2004026678A (ja) | ２型糖尿病治療剤 | |
| CN112384214A (zh) | 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 | |
| US20040152753A1 (en) | Methods of use for novel sulfur containing organic nitrate compounds | |
| JP2022521119A5 (https=) | ||
| WO2011002011A1 (ja) | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 | |
| WO2010050422A1 (ja) | 糖尿病治療剤 | |
| AU2016278040B2 (en) | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof | |
| TW201922249A (zh) | 二羧酸化合物與磷吸附劑之組合 | |
| JPWO2021009506A5 (https=) | ||
| TW592702B (en) | Pharmaceutical composition for treating diabetes | |
| JPWO2022263792A5 (https=) |